KR920019798A - 라파마이신 카바메이트 - Google Patents

라파마이신 카바메이트 Download PDF

Info

Publication number
KR920019798A
KR920019798A KR1019920006033A KR920006033A KR920019798A KR 920019798 A KR920019798 A KR 920019798A KR 1019920006033 A KR1019920006033 A KR 1019920006033A KR 920006033 A KR920006033 A KR 920006033A KR 920019798 A KR920019798 A KR 920019798A
Authority
KR
South Korea
Prior art keywords
carbon atoms
rapamycin
compound according
ester
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019920006033A
Other languages
English (en)
Korean (ko)
Inventor
카오 웬링
루이스 보겔 로버트
헨리 뮤셔 죤
Original Assignee
에곤 이. 버그
아메리칸 홈 프로덕츠 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/686,728 external-priority patent/US5118678A/en
Priority claimed from US07/837,048 external-priority patent/US5194447A/en
Application filed by 에곤 이. 버그, 아메리칸 홈 프로덕츠 코포레이션 filed Critical 에곤 이. 버그
Publication of KR920019798A publication Critical patent/KR920019798A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1019920006033A 1991-04-17 1992-04-11 라파마이신 카바메이트 Withdrawn KR920019798A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/686728 1991-04-17
US07/686,728 US5118678A (en) 1991-04-17 1991-04-17 Carbamates of rapamycin
US07/837,048 US5194447A (en) 1992-02-18 1992-02-18 Sulfonylcarbamates of rapamycin
US07/837048 1992-02-18

Publications (1)

Publication Number Publication Date
KR920019798A true KR920019798A (ko) 1992-11-20

Family

ID=27103855

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920006033A Withdrawn KR920019798A (ko) 1991-04-17 1992-04-11 라파마이신 카바메이트

Country Status (12)

Country Link
EP (1) EP0509795A2 (OSRAM)
JP (1) JPH05112573A (OSRAM)
KR (1) KR920019798A (OSRAM)
AU (1) AU642592B2 (OSRAM)
CZ (1) CZ117392A3 (OSRAM)
FI (1) FI921595L (OSRAM)
HU (1) HU9201254D0 (OSRAM)
IE (1) IE921249A1 (OSRAM)
MX (1) MX9201710A (OSRAM)
NO (1) NO921449L (OSRAM)
NZ (1) NZ242367A (OSRAM)
SK (1) SK117392A3 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776943A (en) * 1991-05-14 1998-07-07 American Home Products Corporation Rapamycin metabolites
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
WO1993018043A1 (en) * 1992-03-05 1993-09-16 American Home Products Corporation Novel rapamycin 42-sulfonates and 42-(n-carboalkoxy)sulfamates useful as immunosuppressive agents
GB9307491D0 (en) * 1993-04-08 1993-06-02 Sandoz Ltd Organic compounds
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
WO1995014023A1 (en) * 1993-11-19 1995-05-26 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ES2222222T3 (es) * 1999-08-18 2005-02-01 Wyeth Esteres hidrosolubles de sdz-rad.
ES2425739T3 (es) 2002-02-11 2013-10-17 Bayer Healthcare Llc Sorafenib-tosilato para el tratamiento de enfermedades caracterizadas por angiogénesis anormal
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
DE602004011340T2 (de) 2003-05-20 2008-11-06 Bayer Healthcare Llc Diaryl-harnstoffe mit kinasehemmender wirkung
NZ544920A (en) 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
WO2005042567A1 (en) * 2003-11-03 2005-05-12 Altachem Pharma Ltd. Rapamycin peptides conjugates: synthesis and uses thereof
US8021849B2 (en) 2004-11-05 2011-09-20 Siemens Healthcare Diagnostics Inc. Methods and kits for the determination of sirolimus in a sample
BRPI0608885A2 (pt) 2005-03-07 2017-02-21 Wyeth Corp composto de isômero c de sdz-rad, composição farmacêutica, e, embalagem farmacêutica
US7189582B2 (en) 2005-04-27 2007-03-13 Dade Behring Inc. Compositions and methods for detection of sirolimus
KR20210131329A (ko) * 2019-01-25 2021-11-02 노드테라 리미티드 카르바메이트 유도체 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
JPH05504944A (ja) * 1989-08-18 1993-07-29 藤沢薬品工業株式会社 巨大環式化合物
PT98990A (pt) * 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin

Also Published As

Publication number Publication date
EP0509795A3 (OSRAM) 1994-03-23
SK117392A3 (en) 1995-04-12
FI921595A0 (fi) 1992-04-10
CZ117392A3 (en) 1993-09-15
EP0509795A2 (en) 1992-10-21
HU9201254D0 (en) 1992-07-28
MX9201710A (es) 1993-01-01
NO921449L (no) 1992-10-19
FI921595A7 (fi) 1992-10-18
NO921449D0 (no) 1992-04-10
AU1488092A (en) 1992-10-22
AU642592B2 (en) 1993-10-21
IE921249A1 (en) 1992-10-21
JPH05112573A (ja) 1993-05-07
FI921595L (fi) 1992-10-18
NZ242367A (en) 1994-07-26

Similar Documents

Publication Publication Date Title
KR920019798A (ko) 라파마이신 카바메이트
NO943583L (no) Stabilisert farmasöytisk preparat og stabiliserende opplösningsmiddel
RU2000104829A (ru) Гетероциклические производные, ингибирующие фактор ха
KR890001537A (ko) 5ht-3 길항제의 용도
KR890005147A (ko) 펩티딜헤테로사이클
BR9608502A (pt) Derivado da pirrola e composição medicinal
AU677868B2 (en) New naphthalene derivatives, processes for their preparation and the pharmaceutical compositions which contain them
KR950016723A (ko) 자가면역 질병의 억제 방법
KR900015721A (ko) 신규 방법 및 화합물들
DK0652002T3 (da) Anvendelse af 2-phenyl-3-aroylebenzothiophener til fremstilling af et medikament til hæmning af brusknedbrydning
WO2003024943A3 (en) Aryl derivatives for the treatment of diabetes, hyperlipidemia, hypercholesterolemia and atherosclerosis
WO2001081328A3 (en) Thiazolidinedione analogues and their use for the treatment of diabetes
RU96123713A (ru) Тиадиазолы и их применение в качестве противопикорнавирусного средства
EA199900510A1 (ru) Инъекционное лекарственное средство "цитофлавин", обладающее цитопротекторным действием
TR200103144T2 (tr) Yeni bileşikler
RU98106104A (ru) Производные пиримидина
EP0601183A4 (en) ANTI-HIV MEDICINE.
RU99125325A (ru) Замещенное производное циклобутиламина
KR880002528A (ko) 뇌세포 보호작용을 가지는 의약 조성물
BRPI0417747A (pt) uso de compostos orgánicos
KR950702561A (ko) 퀴놀린 및 나프티리딘 약물 전구체(quinoline and naphthyridine prodrugs)
ES2080175T3 (es) Estabilizador para una preparacion que contiene 4-etil-2-hidroxiimino-5-nitro-3-hexenamida y metodo de estabilizacion correspondiente.
KR980002033A (ko) 트리아졸 유도체 또는 그 염
ES2102370T3 (es) Composicion antiparasitaria para uso animal.
KR900001696A (ko) 궤양치료 활성을 갖는 1.4-디아제핀 유도체

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19920411

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid